Literature DB >> 17616679

Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis.

Thomas R Geiger1, Daniel S Peeper.   

Abstract

Anoikis, or cell death induced by cell detachment, provides protection against the metastatic spread of tumor cells. We have previously shown that the neurotrophic receptor tyrosine kinase TrkB suppresses anoikis in rat intestinal epithelial cells and renders them highly tumorigenic and metastatic. Because TrkB is overexpressed in several aggressive human cancers, first attempts are being made to target TrkB in cancer therapy. However, the mechanisms underlying TrkB-mediated anoikis suppression, tumorigenesis, and metastasis still remain largely elusive. Although, to date, most attempts to neutralize TrkB in tumors aim to inactivate its kinase activity, it is unclear whether TrkB kinase activity is required for its oncogenic functions. Indeed, it has been suggested that also other properties of the receptor contribute to functions that are relevant to tumor cell survival. Specifically, several adhesion motifs reside within the extracellular domains of TrkB. In line with this, TrkB-expressing epithelial cells form large cellular aggregates in suspension cultures, possibly facilitating tumor cell survival. Therefore, we set out to study the relative contributions of TrkB's kinase activity and its adhesion domains to anoikis suppression and oncogenicity. On the basis of a structure-function analysis, we report that TrkB kinase activity is required and, unexpectedly, also sufficient for anoikis suppression, tumor formation, and experimental metastasis. Thus, TrkB can act tumorigenically independent of its adhesion motifs. These results suggest that targeting the enzymatic activity of TrkB might be beneficial in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616679     DOI: 10.1158/0008-5472.CAN-07-0121

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cells.

Authors:  Yuen-Keng Ng; Elaine Yue Ling Wong; Cecilia Pik Yuk Lau; Jessica Pui Lan Chan; Sze Chuen Cesar Wong; Andrew Sai-Kit Chan; Maggie Pui Chun Kwan; Sai-Wah Tsao; Chi-Man Tsang; Paul Bo San Lai; Anthony Tak Cheung Chan; Vivian Wai Yan Lui
Journal:  Invest New Drugs       Date:  2010-08-07       Impact factor: 3.850

Review 2.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

3.  A transfection method of PS-asODNs targeting ANGPTL4 in multicellular structures of hepatocarcinoma cell line.

Authors:  Q Kong; G Wu; L Han; Z Zhang; J Du; W Sun; L Cao
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

4.  TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung.

Authors:  Alberto Ricci; Claudia De Vitis; Alessia Noto; Luigi Fattore; Salvatore Mariotta; Emanuela Cherubini; Giuseppe Roscilli; Giuseppina Liguori; Giosuè Scognamiglio; Gaetano Rocco; Gerardo Botti; Enrico Giarnieri; Maria Rosaria Giovagnoli; Giorgio De Toma; Gennaro Ciliberto; Rita Mancini
Journal:  Cell Cycle       Date:  2013-05-02       Impact factor: 4.534

5.  The role of multicellular aggregation in the survival of ErbB2-positive breast cancer cells during extracellular matrix detachment.

Authors:  Raju R Rayavarapu; Brendan Heiden; Nicholas Pagani; Melissa M Shaw; Sydney Shuff; Siyuan Zhang; Zachary T Schafer
Journal:  J Biol Chem       Date:  2015-02-13       Impact factor: 5.157

Review 6.  Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression.

Authors:  Cassandra L Buchheit; Kelsey J Weigel; Zachary T Schafer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

7.  High-affinity neurotrophin receptors and ligands promote leukemogenesis.

Authors:  Zhixiong Li; Gernot Beutel; Mathias Rhein; Johann Meyer; Christian Koenecke; Thomas Neumann; Min Yang; Jürgen Krauter; Nils von Neuhoff; Michael Heuser; Helmut Diedrich; Gudrun Göhring; Ludwig Wilkens; Brigitte Schlegelberger; Arnold Ganser; Christopher Baum
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

8.  TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells.

Authors:  Siyang Zhang; Dawei Guo; Wenting Luo; Qingfu Zhang; Ying Zhang; Chunyan Li; Yao Lu; Zeshi Cui; Xueshan Qiu
Journal:  BMC Cancer       Date:  2010-02-16       Impact factor: 4.430

9.  Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Authors:  Christophe J Desmet; Tristan Gallenne; Alexandre Prieur; Fabien Reyal; Nils L Visser; Ben S Wittner; Marjon A Smit; Thomas R Geiger; Jamila Laoukili; Sedef Iskit; Boris Rodenko; Wilbert Zwart; Bastiaan Evers; Hugo Horlings; Abderrahrim Ajouaou; John Zevenhoven; Martin van Vliet; Sridhar Ramaswamy; Lodewyk F A Wessels; Daniel S Peeper
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-12       Impact factor: 11.205

10.  Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Authors:  Diana M Cittelly; Irina Dimitrova; Erin N Howe; Dawn R Cochrane; Annie Jean; Nicole S Spoelstra; Miriam D Post; Xian Lu; Russell R Broaddus; Monique A Spillman; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2012-10-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.